Kymera Therapeutics Inc [KYMR] stock is trading at $43.13, up 45.51%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The KYMR shares have gain 46.25% over the last week, with a monthly amount glided 24.83%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kymera Therapeutics Inc [NASDAQ: KYMR] stock has seen the most recent analyst activity on June 02, 2025, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $51 for it. On March 13, 2025, Citigroup initiated with a Buy rating and assigned a price target of $52 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $60 on December 10, 2024. BMO Capital Markets initiated its recommendation with a Market Perform and recommended $55 as its price target on December 06, 2024. Wells Fargo upgraded its rating to Overweight for this stock on December 02, 2024, but kept the price target unchanged to $57. In a note dated November 18, 2024, Stephens initiated an Overweight rating and provided a target price of $65 on this stock.
Kymera Therapeutics Inc [KYMR] stock has fluctuated between $19.44 and $53.27 over the past year. Currently, Wall Street analysts expect the stock to reach $54.5 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $43.13 at the most recent close of the market. An investor can expect a potential return of 26.36% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
Kymera Therapeutics Inc [NASDAQ:KYMR] reported sales of 58.88M for the trailing twelve months, which represents a growth of 114.83%. Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at -4.72%, Pretax Profit Margin comes in at -4.09%, and Net Profit Margin reading is -4.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.3 and Total Capital is -0.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 38.67 points at the first support level, and at 34.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 45.78, and for the 2nd resistance point, it is at 48.42.
Ratios To Look Out For
For context, Kymera Therapeutics Inc’s Current Ratio is 8.49. In addition, the Quick Ratio stands at 8.49 and the Cash Ratio stands at 1.53. Considering the valuation of this stock, the price to sales ratio is 47.70, the price to book ratio is 3.57.
Transactions by insiders
Recent insider trading involved Chadwick Jeremy G, Chief Operating Officer, that happened on May 23 ’25 when 2575.0 shares were sold. Officer, Chadwick Jeremy G completed a deal on May 23 ’25 to buy 2575.0 shares. Meanwhile, Chief Legal Officer Chiniara Ellen sold 2241.0 shares on Mar 03 ’25.
